Stay updated on Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now includes a new site revision tag: Revision: v3.4.2. The older funding-status notice and the earlier Revision: v3.4.1 text have been removed.SummaryDifference0.3%

- Check12 days agoChange DetectedAdded a government funding lapse notice regarding NIH site status and updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check19 days agoChange DetectedA new 'Show glossary' option was added to the page interface, and several metadata labels were updated (e.g., 'Last Update Submitted that Met QC Criteria', 'No FEAR Act data') with the revision note showing 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check55 days agoChange DetectedLocations section expanded to list multiple new sites (Beijing Municipality, Fujian, Jiangsu, Jilin, Shanxi, Zhejiang, Kuala Lumpur, Gyeonggi-do) and corresponding individual location subsections were removed, along with the HHS Vulnerability Disclosure link.SummaryDifference0.7%

- Check76 days agoChange DetectedThe page footer revision label updated from v3.3.1 to v3.3.2. No other content or study details were changed.SummaryDifference0.0%

- Check83 days agoChange DetectedPublications section now states that publications are automatically filled in from PubMed, and the page revision is updated to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.